Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 Hours
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1395 participants.
Also called NCT07931807
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,395 participants
- Registry
-
NCT07931807
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07931807. Randomized; single masking; primary purpose treatment. Start 2026-12 (anticipated); primary completion 2029-04-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 Hours
- Acronym
- ORIENTAL-MeVO2
- Condition
- Medium Vessel Occlusion Stroke (MeVO)
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Tenecteplase
- Intervention (Procedure)
- Endovascular Treatment
- Lead sponsor
- The First Affiliated Hospital of University of Science and Technology of China
Record details
- Record id
cardio:ct-nct07931807- Content hash
ec1507e68ae401ccfcb7d14367760de94bc2606fe2ca5d826347674c25813492